Larry Goldenberg, OBC (born 1953 in Toronto, Ontario) is an award-winning Canadian researcher in the field of medicine and a pioneer in the treatment of prostate cancer.
Goldenberg is recognized around the world as being one of the first researchers and medical practitioners to compare the practical effectiveness of intermittent androgen suppression (I.A.S.) as a treatment alternative to continuous hormonal therapy for patients with advanced case...
more
Larry Goldenberg, OBC (born 1953 in Toronto, Ontario) is an award-winning Canadian researcher in the field of medicine and a pioneer in the treatment of prostate cancer.
Goldenberg is recognized around the world as being one of the first researchers and medical practitioners to compare the practical effectiveness of intermittent androgen suppression (I.A.S.) as a treatment alternative to continuous hormonal therapy for patients with advanced cases of prostate cancer. His work with IAS has provided the scientific basis for a number of prominent international Phase II and III clinical trials.
Goldenberg spearheaded the clinical development of a low-dose antiandrogen/DES protocol that was among the leading treatment options for advanced prostate cancer until the mid-1990s. He was also one of the co-developers of clinical protocols for the use of neoadjucant hormonal therapy before radical prostatectomy.
Goldenberg's present lab and clinical research undertakings centre on the potential...
less
